Key result
In nondialysed CKD patients, flow-mediated dilatation and C-reactive protein independently predicted fatal and nonfatal cardiovascular outcomes.
Why the study?
Do flow-mediated dilatation (FMD), intima-media thickness (IMT), and C-reactive protein (CRP) predict cardiovascular outcomes in nondialysed chronic kidney disease patients?
Cohort (n=304)
Do flow-mediated dilatation (FMD), intima-media thickness (IMT), and C-reactive protein (CRP) predict cardiovascular outcomes in nondialysed chronic kidney disease patients?
Answers are grounded in this paper and cite their sources.
Endothelial dysfunction (measured by FMD) and inflammation (CRP) independently predict cardiovascular outcomes in nondialysed CKD patients, supporting the use of FMD over IMT for risk stratification.
INTRODUCTION: Systemic inflammation, endothelial dysfunction and arterial thickening contribute to the elevated cardiovascular risk of dialysis patients. However, the course of these derangements and their relative contribution to the cardiovascular risk of nondialysed chronic kidney disease (CKD) are scarcely investigated. METHODS: Flow-mediated dilatation (FMD) and intima-media thickness (IMT) were assessed in 304 nondialysed CKD patients Stages 1-5 (mean age 46 ± 12 years, 158 men), together with routine biochemical measurements, C-reactive protein (CRP) and insulin resistance. Patients were then followed for time-to-event analysis of cardiovascular outcomes (fatal and nonfatal). RESULTS: CRP and IMT increased, while FMD decreased in parallel with estimated glomerular filtration rate (eGFR) decline (P < 0.001 for all). CRP and intact parathormone, as well as eGFR, appeared as strong determinants of FMD and IMT in multivariate analyses. After a median follow-up of 41 (range 6-46) months, 30 fatal and 59 nonfatal cardiovascular events occurred. In univariate analysis, FMD, IMT and CRP were significant predictors of outcome. In a multivariate Cox model excluding IMT, both FMD [hazard ratios 0.52 (95% confidence intervals 0.37-0.73) per %] and CRP [1.07 (1.03-1.11) per mg/L] predicted cardiovascular outcomes independently of confounders. In a model excluding FMD, only CRP (and not IMT) was a significant predictor. CONCLUSIONS: Endothelial dysfunction, arterial thickening and inflammation occur in parallel with the decline in eGFR, contributing to the increased cardiovascular risk of nondialysed CKD. Our results support the use of FMD over IMT measurements to monitor nondialysed CKD patients at risk.
No takes yet. Share an insight, caveat, or question.
Yılmaz et al. (2011) conducted a cohort in Nondialysed chronic kidney disease (CKD) Stages 1-5 (n=304). Flow-mediated dilatation (FMD) and C-reactive protein (CRP) was evaluated on Cardiovascular outcomes (fatal and nonfatal) (HR 0.52, 95% CI 0.37-0.73). In nondialysed CKD patients, flow-mediated dilatation and C-reactive protein independently predicted fatal and nonfatal cardiovascular outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: